Understanding Your Severe Asthma Biologic (Dupilumab, Omalizumab, etc.) Denial
Biologic medications for severe asthma, such as omalizumab, dupilumab, and others, are often denied because insurers say you have not met exact lab criteria, have not failed enough inhalers, or your asthma is not severe enough. These denials ignore how dangerous uncontrolled asthma can be.
Common Reasons for Denial
- ! Does not meet blood eosinophil or IgE thresholds
- ! Insufficient trial of high-dose inhaled corticosteroids and other controllers
- ! Asthma not documented as severe or uncontrolled
- ! Non-formulary biologic requested when a different one is preferred
How We Help
We help you explain your asthma history, ER visits, oral steroid bursts, and test results so that an appeal clearly shows you meet guideline-based criteria for a biologic and that ongoing uncontrolled asthma is unsafe and costly.
Some Types of Evidence We Can Use For Supporting Your Appeal
✓ Biologic therapies for severe asthma reduce exacerbation rates and oral steroid use in appropriately selected patients.
✓ Uncontrolled asthma is associated with frequent ER visits, hospitalizations, and impaired quality of life.
✓ Guidelines recommend escalation to biologic therapy when high-dose inhaled therapies do not adequately control disease.
Patient Advocacy & Support Organizations
These organizations provide education, support, and advocacy for patients:
Asthma and Allergy Foundation of America ↗
Leading patient advocacy organization for asthma and allergies, certified by National Health Council.
Allergy & Asthma Network ↗
Nonprofit patient outreach, education, advocacy and research organization.
Frequently Asked Questions
Ready to Fight Your Severe Asthma Biologic (Dupilumab, Omalizumab, etc.) Denial?
Our free AI-powered tool will help you generate a compelling appeal letter in minutes.
Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.